ANTENGENE CORP. DL-0001 (F:722) — Market Cap & Net Worth
Market Cap & Net Worth: ANTENGENE CORP. DL-0001 (722)
ANTENGENE CORP. DL-0001 (F:722) has a market capitalization of $288.55 Million (€246.81 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #14964 globally and #1483 in its home market, demonstrating a -6.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANTENGENE CORP. DL-0001's stock price €0.40 by its total outstanding shares 610925912 (610.93 Million). Review ANTENGENE CORP. DL-0001 (722) total liabilities to assess the company's total debt and financial obligations.
ANTENGENE CORP. DL-0001 Market Cap History: 2021 to 2026
ANTENGENE CORP. DL-0001's market capitalization history from 2021 to 2026. Data shows change from $764.23 Million to $288.55 Million (-24.05% CAGR).
ANTENGENE CORP. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANTENGENE CORP. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.69x
ANTENGENE CORP. DL-0001's market cap is 2.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $764.23 Million | $28.77 Million | -$655.53 Million | 26.56x | N/A |
| 2022 | $428.54 Million | $160.13 Million | -$601.49 Million | 2.68x | N/A |
| 2023 | $147.13 Million | $67.31 Million | -$581.18 Million | 2.19x | N/A |
| 2024 | $45.71 Million | $91.95 Million | -$319.25 Million | 0.50x | N/A |
| 2025 | $282.84 Million | $105.34 Million | -$239.13 Million | 2.69x | N/A |
Competitor Companies of 722 by Market Capitalization
Companies near ANTENGENE CORP. DL-0001 in the global market cap rankings as of August 4, 2026.
Key companies related to ANTENGENE CORP. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
ANTENGENE CORP. DL-0001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ANTENGENE CORP. DL-0001's market cap moved from $764.23 Million to $ 288.55 Million, with a yearly change of -24.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €288.55 Million | +2.02% |
| 2025 | €282.84 Million | +518.75% |
| 2024 | €45.71 Million | -68.93% |
| 2023 | €147.13 Million | -65.67% |
| 2022 | €428.54 Million | -43.93% |
| 2021 | €764.23 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of ANTENGENE CORP. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $288.55 Million USD |
| MoneyControl | $288.55 Million USD |
| MarketWatch | $288.55 Million USD |
| marketcap.company | $288.55 Million USD |
| Reuters | $288.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more